Medtronic’s MDT acquisition of Covidien has produced a combined company that’s a force to be reckoned with in medical technology. Pairing Medtronic’s diversified product portfolio aimed at a wide ...

Two patients who were injured by Medtronic's controversial Infuse bone graft product will receive a combined $8.45 million in settlements with the University of California Los Angeles, where a doctor ...

The experiences of one surgeon are raising questions about the costs and risks of a Medtronic Inc. (MDT) bone-growth product, threatening to pressure further the company's spinal business. According ...

Medtronic ended its fiscal year with nominal sales growth and a steep profit drop, but analysts who cover the medical device company are confident a windfall is ahead, thanks to a strong lineup of ...

Fridley-based Medtronic, Inc., recently received a letter from two U.S. senators requesting information about the use of the company's Infuse bone-growth product and payments it made to clinical ...

Cardinal Health has reached a definitive agreement to buy several of Medtronic’s medical device lines for $6.1 billion in cash. The deal, announced Tuesday, gives Cardinal access to 23 product ...

An unresolved warning letter from the Food and Drug Administration continues to cause trouble for the heart device division at Fridley-based Medtronic. After releasing second-quarter results earlier ...

A little more than a month after Medtronic ($MDT) closed its $49.9 billion purchase of Covidien, the combined company is forging ahead with ambitious plans for growth ...

MILWAUKEE — In January 2002, a group of Food and Drug Administration advisers met on whether to approve a powerful new biological agent that promised to revolutionize back surgery. The product was ...

Medtronic is buying Covidien in a tax-friendly move, but here are three other reasons the deal makes sense. The two companies have big and growing businesses that complement one another, too. Here are ...

Two aspects of the recently reported fiscal third quarter were particularly noteworthy, from our perspective. First, management’s comments regarding the Guardian Connect continuous glucose monitor ...